Searching for the optimal cyclosporin A treatment method for atopic dermatitis

Searching for the optimal cyclosporin A treatment method for atopic dermatitis - Treatment with cyclosporin A for atopic dermatitis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004284

Enrollment

Registered

2010-09-28

Start date

2010-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

atopic dermatitis

Interventions

cessation of drug after 3 months (no dose reduction) cessation of drug after 3 months (dose reduction) continuous dosing (no dose reduction) continuous dosing (dose reduction)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) diagnosis of severe atopic dermatitis 2) intractable case with atopic dermatitis (resistant with ordinary dose of steroid ointment application) 3)over 16 years old 4) acceptable economic matters for patients 5) patients are no contraindication to cyclosporin A. 6) Regardless of gender

Exclusion criteria

Exclusion criteria: 1) patients are contraindication to cyclosporin A 2) patients are required careful administration of cyclosporin A 3) Patients during the PUVA therapy 4) excluding at aphysician's direction

Design outcomes

Primary

Measure	Time frame
1) severity of atopic dermatitis with scoring by Rajka&Langeland. 2) serum TARC level 3) used amount of ointment. 4) ratio and duration of disease flare-up. 5) QOL with DLQI, itch VAS, and sleep disturbance VAS.	—

Countries

Japan

Contacts

Public Contact0668795111

Osaka univeristy Dermatology

h-murota@derma.med.osaka-u.ac.jp0668795111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026